Article
China’s Rise As A Global Biopharma Innovation Hub: Navigating Trends, Opportunities, And Evolving Deal Structures
China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato
WilmerHale